ATE190838T1 - Injizierbare arzneizubereitungen enthaltend taxanderivate - Google Patents

Injizierbare arzneizubereitungen enthaltend taxanderivate

Info

Publication number
ATE190838T1
ATE190838T1 AT94900881T AT94900881T ATE190838T1 AT E190838 T1 ATE190838 T1 AT E190838T1 AT 94900881 T AT94900881 T AT 94900881T AT 94900881 T AT94900881 T AT 94900881T AT E190838 T1 ATE190838 T1 AT E190838T1
Authority
AT
Austria
Prior art keywords
preparations containing
medicinal preparations
injectable medicinal
derivatives
taxan derivatives
Prior art date
Application number
AT94900881T
Other languages
English (en)
Inventor
Jean-Marc Bobee
Lanty Patrick De
Gilles Guerin
Michel Veillard
Original Assignee
Rhone Poulenc Rorer Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=9436137&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE190838(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Rhone Poulenc Rorer Sa filed Critical Rhone Poulenc Rorer Sa
Application granted granted Critical
Publication of ATE190838T1 publication Critical patent/ATE190838T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Dermatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Epoxy Compounds (AREA)
  • Detergent Compositions (AREA)
AT94900881T 1992-12-02 1993-11-26 Injizierbare arzneizubereitungen enthaltend taxanderivate ATE190838T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR9214501A FR2698543B1 (fr) 1992-12-02 1992-12-02 Nouvelles compositions à base de taxoides.
PCT/FR1993/001166 WO1994012171A1 (fr) 1992-12-02 1993-11-26 Compositions injectables a base de derives des taxanes

Publications (1)

Publication Number Publication Date
ATE190838T1 true ATE190838T1 (de) 2000-04-15

Family

ID=9436137

Family Applications (1)

Application Number Title Priority Date Filing Date
AT94900881T ATE190838T1 (de) 1992-12-02 1993-11-26 Injizierbare arzneizubereitungen enthaltend taxanderivate

Country Status (28)

Country Link
US (1) US5438072A (de)
EP (1) EP0671912B1 (de)
JP (1) JP3689791B2 (de)
KR (1) KR100330316B1 (de)
CN (2) CN1090170A (de)
AT (1) ATE190838T1 (de)
AU (1) AU691476B2 (de)
CA (1) CA2150576C (de)
CZ (1) CZ284080B6 (de)
DE (2) DE69328192D1 (de)
DK (1) DK0671912T3 (de)
ES (1) ES2145115T4 (de)
FI (1) FI113619B (de)
FR (1) FR2698543B1 (de)
GE (1) GEP19991856B (de)
GR (1) GR3032828T3 (de)
HU (1) HU222833B1 (de)
MX (1) MX9306986A (de)
NO (1) NO314436B1 (de)
NZ (1) NZ258150A (de)
PL (1) PL174334B1 (de)
PT (1) PT671912E (de)
RU (1) RU2144356C1 (de)
SK (1) SK281558B6 (de)
TW (1) TW271395B (de)
WO (1) WO1994012171A1 (de)
YU (1) YU49092B (de)
ZA (1) ZA938936B (de)

Families Citing this family (120)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5994341A (en) * 1993-07-19 1999-11-30 Angiogenesis Technologies, Inc. Anti-angiogenic Compositions and methods for the treatment of arthritis
ATE154757T1 (de) 1993-07-19 1997-07-15 Angiotech Pharm Inc Anti-angiogene mittel und verfahren zu deren verwendung
US5681846A (en) * 1995-03-17 1997-10-28 Board Of Regents, The University Of Texas System Extended stability formulations for paclitaxel
US6395770B1 (en) * 1995-10-26 2002-05-28 Baker Norton Pharmaceuticals, Inc. Method and compositions for administering taxanes orally to human patients
US6964946B1 (en) * 1995-10-26 2005-11-15 Baker Norton Pharmaceuticals, Inc. Oral pharmaceutical compositions containing taxanes and methods of treatment employing the same
US6245805B1 (en) 1995-10-26 2001-06-12 Baker Norton Pharmaceuticals, Inc. Method, compositions and kits for increasing the oral bioavailability of pharmaceutical agents
EP0876145A4 (de) * 1995-12-21 1999-04-21 Genelabs Tech Inc Taxanzusammensetzung und verfahren
KR100191446B1 (ko) * 1996-05-02 1999-06-15 송영욱 파클리탁셀 함유 전신성 홍반성 낭창치료제
AU737078C (en) 1996-05-24 2002-05-02 Angiotech Pharmaceuticals, Inc. Compositions and methods for treating or preventing diseases of body passageways
KR100330373B1 (ko) * 1996-05-28 2002-11-07 주식회사한국신약 탁솔을 함유한 주사용 약제 조성물
WO1998053810A1 (en) * 1997-05-30 1998-12-03 Man Woo Han Pharmaceutical injection solution containing taxol
US5877205A (en) * 1996-06-28 1999-03-02 Board Of Regents, The University Of Texas System Parenteral paclitaxel in a stable non-toxic formulation
KR100358934B1 (ko) * 1996-09-13 2003-01-29 주식회사한국신약 탁솔을함유한주사용약제조성물
DE19655141C5 (de) 1996-11-08 2013-12-05 Eppendorf Ag Gradienten-Temperierblock für Laborthermostaten
US6515016B2 (en) 1996-12-02 2003-02-04 Angiotech Pharmaceuticals, Inc. Composition and methods of paclitaxel for treating psoriasis
AU741439B2 (en) * 1996-12-30 2001-11-29 Battelle Memorial Institute Formulation and method for treating neoplasms by inhalation
HUP0002922A3 (en) * 1997-04-28 2003-03-28 Aventis Pharma Sa Adenovirus-mediated intratumoral delivery of an angiogenesis antagonist for the treatment of tumors
CN1101677C (zh) * 1997-05-30 2003-02-19 韩万愚 含有紫杉醇的药用注射溶液
BE1011216A3 (fr) * 1997-06-13 1999-06-01 Thissen En Abrege L T B Lab Forme pharmaceutique pour l'administration de paclitaxel, procede de preparation d'une composition de paclitaxel prete a l'emploi et utilisation de cette composition.
US5925776A (en) * 1997-12-24 1999-07-20 Schein Pharmacetical, Inc. Polyethoxylated castor oil, process of making the same and formulations thereof
GB9803448D0 (en) * 1998-02-18 1998-04-15 Pharma Mar Sa Pharmaceutical formulation
US5922754A (en) * 1998-10-02 1999-07-13 Abbott Laboratories Pharmaceutical compositions containing paclitaxel
US6071952A (en) * 1998-12-02 2000-06-06 Mylan Pharmaceuticals, Inc. Stabilized injectable pharmaceutical compositions containing taxoid anti-neoplastic agents
FR2794771B1 (fr) * 1999-06-11 2001-08-10 Aventis Pharma Sa Adenovirus recombinants codant pour le transporteur specifique de l'iode (nis)
HK1049787B (en) 1999-10-01 2014-07-25 Immunogen, Inc. Compositions and methods for treating cancer using immunoconjugates and chemotherapeutic agents
WO2001035974A2 (en) * 1999-11-15 2001-05-25 Pharma Mar S.A. Aplidine treatment of cancers
CA2367661A1 (en) * 2000-02-02 2001-08-09 Robert A. Holton Taxane formulations having improved solubility
KR20010100194A (ko) * 2000-03-13 2001-11-14 박호군 여러 가지 물질의 가용화용 조성물과 제형 및 그들의제조방법
US6919370B2 (en) * 2000-11-28 2005-07-19 Transform Pharmaceuticals, Inc. Pharmaceutical formulations comprising paclitaxel, derivatives, and pharmaceutically acceptable salts thereof
US20040241094A1 (en) * 2001-09-13 2004-12-02 Hesson Chung Oily paclitaxel composition and formulation for chemoembolization and preparation method thereof
DE60229414D1 (de) * 2001-10-19 2008-11-27 Pharma Mar Sa Verwendung von aplidine in der behandlung von pankreaskrebs
WO2003045357A1 (en) * 2001-11-27 2003-06-05 Transform Pharmaceuticals, Inc. Oral pharmaceutical formulations comprising paclitaxel, derivatives and methods of administration thereof
US8313760B2 (en) 2002-05-24 2012-11-20 Angiotech International Ag Compositions and methods for coating medical implants
CA2484761C (en) * 2002-05-24 2010-11-09 Angiotech International Ag Compositions and methods for coating medical implants
KR100533458B1 (ko) * 2002-07-20 2005-12-07 대화제약 주식회사 파클리탁셀의 가용화용 조성물 및 그의 제조 방법
JP2006502301A (ja) 2002-09-06 2006-01-19 インサート セラピューティクス インコーポレイテッド 治療剤配送のためのシクロデキストリン基材重合体
US20080220074A1 (en) * 2002-10-04 2008-09-11 Elan Corporation Plc Gamma radiation sterilized nanoparticulate docetaxel compositions and methods of making same
AU2004293075A1 (en) * 2003-11-20 2005-06-09 Angiotech International Ag Soft tissue implants and anti-scarring agents
DK1792927T3 (da) 2004-09-22 2013-06-10 Nippon Kayaku Kk Ny blokcopolymer, micelletilberedning og anticancermiddel indeholdende samme som aktiv ingrediens
AU2005100176A4 (en) * 2005-03-01 2005-04-07 Gym Tv Pty Ltd Garbage bin clip
SG162798A1 (en) 2005-06-17 2010-07-29 Hospira Australia Pty Ltd Liquid pharmaceutical formulations of docetaxel
GB0517092D0 (en) * 2005-08-19 2005-09-28 Novartis Ag New compositions containing taxane derivatives
AR054215A1 (es) * 2006-01-20 2007-06-13 Eriochem Sa Una formulacion farmaceutica de un taxano, una composicion solida de un taxano liofilizado a partir de una solucion de acido acetico, un procedimiento para la preparacion de dicha composicion solida de un taxano, una composicion solubilizante de un taxano liofilizado, y un conjunto de elementos (kit
BRPI0600194A (pt) 2006-01-30 2007-10-23 Quiral Quimica Do Brasil S A composições farmacêuticas contendo docetaxel e um inibidor de degradação e processo de obtenção das mesmas
CN101023940A (zh) * 2006-02-20 2007-08-29 郝守祝 一种紫杉烷类化合物的药用组合物、制备方法及用途
WO2007111211A1 (ja) * 2006-03-28 2007-10-04 Nippon Kayaku Kabushiki Kaisha タキサン類の高分子結合体
US8940332B2 (en) 2006-05-18 2015-01-27 Nippon Kayaku Kabushiki Kaisha High-molecular weight conjugate of podophyllotoxins
CA2664852A1 (en) * 2006-10-03 2008-04-10 Nippon Kayaku Kabushiki Kaisha High-molecular weight conjugate of resorcinol derivatives
US8334364B2 (en) 2006-11-06 2012-12-18 Nipon Kayaku Kabushiki Kaisha High-molecular weight derivative of nucleic acid antimetabolite
EP2090607B1 (de) 2006-11-08 2015-05-20 Nippon Kayaku Kabushiki Kaisha Polymerderivat eines nukleinsäuremetabolismus-antagonisten
WO2008086002A2 (en) 2007-01-08 2008-07-17 Government Of The Usa, As Represented By The Secretary, Department Of Health And Human Services Slco1b3 genotype
CZ200756A3 (cs) * 2007-01-23 2008-07-30 Heaton, A. S. Dvousložková farmaceutická kompozice obsahující taxan
JP2010516625A (ja) 2007-01-24 2010-05-20 インサート セラピューティクス， インコーポレイテッド 制御された薬物送達のためのテザー基を有するポリマー−薬物コンジュゲート
CN101244053B (zh) * 2007-02-16 2010-12-08 石药集团中奇制药技术（石家庄）有限公司 以多西他赛为主组分的新的分散体系
WO2009007992A2 (en) * 2007-04-20 2009-01-15 Sun Pharmaceutical Industries Limited Pharmaceutical composition produced by microprecipitation
NZ581589A (en) * 2007-06-22 2012-10-26 Scidose Llc Solubilized sterile injectable formulation of docetaxel without Tween 80
WO2009041570A1 (ja) 2007-09-28 2009-04-02 Nippon Kayaku Kabushiki Kaisha ステロイド類の高分子結合体
CN101396354B (zh) * 2007-09-30 2010-12-01 江苏恒瑞医药股份有限公司 一种稳定的塔三烷类化合物液体组合物及其制备方法和其应用
WO2009047794A2 (en) * 2007-10-01 2009-04-16 Intas Pharmaceuticals Limited Taxane derivative composition
AR063111A1 (es) 2007-10-03 2008-12-30 Eriochem Sa Una formulacion farmaceutica de taxano
FR2922107B1 (fr) * 2007-10-10 2010-02-26 Aventis Pharma Sa Nouvelles compositions a base de taxoides
AU2008352603B2 (en) 2008-03-14 2012-05-31 Bionumerik Pharmaceuticals, Inc. Compositions and methods of use of compounds to increase cancer patient survival time
EP2249825B1 (de) 2008-03-14 2015-10-07 Bionumerik Pharmaceuticals, Inc. Behandlungsverfahren und zusammensetzungen gegen lungenkrebs, adenokarzinom und andere medizinische krankheitszustände
CN101977631A (zh) * 2008-03-18 2011-02-16 日本化药株式会社 生理活性物质的高分子量偶联物
KR102449659B1 (ko) 2008-03-18 2022-09-29 제넨테크, 인크. 항-ｈｅｒ２ 항체-약물 접합체와 화학요법제의 병용물, 및 사용 방법
US9149540B2 (en) 2008-05-08 2015-10-06 Nippon Kayaku Kabushiki Kaisha Polymer conjugate of folic acid or folic acid derivative
RU2428175C2 (ru) * 2008-06-02 2011-09-10 Закрытое Акционерное Общество "Биокад" Способ получения парентерального фармацевтического раствора
ES2344674B1 (es) 2008-08-07 2011-06-29 Gp Pharm, S.A. Composicion farmaceutica inyectable de taxanos.
KR101671537B1 (ko) 2008-08-11 2016-11-01 넥타르 테라퓨틱스 다분지형 중합체 알카노에이트 컨쥬게이트
US8541360B2 (en) * 2008-11-19 2013-09-24 Ben Venue Laboratories, Inc. Parenteral formulations comprising sugar-based esters and ethers
JP2012520314A (ja) 2009-03-11 2012-09-06 アムビト ビオスシエンセス コルポラチオン 癌治療のためのインダゾリルアミノピロロトリアジンとタキサンの併用
WO2010131675A1 (ja) 2009-05-15 2010-11-18 日本化薬株式会社 水酸基を有する生理活性物質の高分子結合体
US7772274B1 (en) 2009-10-19 2010-08-10 Scidose, Llc Docetaxel formulations with lipoic acid
US8912228B2 (en) 2009-10-19 2014-12-16 Scidose Llc Docetaxel formulations with lipoic acid
US20110092579A1 (en) * 2009-10-19 2011-04-21 Scidose Llc Solubilized formulation of docetaxel
US8476310B2 (en) 2009-10-19 2013-07-02 Scidose Llc Docetaxel formulations with lipoic acid
US8541465B2 (en) * 2009-10-19 2013-09-24 Scidose, Llc Docetaxel formulations with lipoic acid and/or dihydrolipoic acid
PL2493466T3 (pl) 2009-10-29 2021-11-15 Sanofi Mature Ip Nowe przeciwguzowe zastosowanie kabazytakselu
CN102781237A (zh) * 2009-11-23 2012-11-14 天蓝制药公司 用于传递治疗剂的基于环糊精的聚合物
US20110165155A1 (en) 2009-12-04 2011-07-07 Genentech, Inc. Methods of treating metastatic breast cancer with trastuzumab-mcc-dm1
PH12012501361A1 (en) 2009-12-31 2012-10-22 Centro Nac De Investigaciones Oncologicas Cnio Tricyclic compounds for use as kinase inhibitors
CA2787714C (en) 2010-01-22 2019-04-09 Joaquin Pastor Fernandez Inhibitors of pi3 kinase
EP2536720A1 (de) 2010-02-18 2012-12-26 Centro Nacional de Investigaciones Oncológicas (CNIO) Triazol-[4, 5 - b]pyridinderivate
TWI438009B (zh) * 2010-02-19 2014-05-21 Teikoku Pharma Usa Inc 紫杉烷前－乳劑調配物及其製造與使用之方法
WO2011121317A1 (en) 2010-04-01 2011-10-06 Centro Nacional De Investigaciones Oncologicas (Cnio) Imidazo [2,1-b] [1,3,4] thiadiazoles as protein or lipid kinase inhibitors
EP2566474B1 (de) 2010-05-03 2017-11-15 Teikoku Pharma USA, Inc. Nichtwässrige taxan-pro-emulsionsformulierungen sowie verfahren zu ihrer herstellung und verwendung
WO2012052745A1 (en) 2010-10-21 2012-04-26 Centro Nacional De Investigaciones Oncológicas (Cnio) Combinations of pi3k inhibitors with a second anti -tumor agent
US9018323B2 (en) 2010-11-17 2015-04-28 Nippon Kayaku Kabushiki Kaisha Polymer derivative of cytidine metabolic antagonist
WO2012088445A1 (en) 2010-12-22 2012-06-28 Nektar Therapeutics Multi-arm polymeric prodrug conjugates of cabazitaxel-based compounds
WO2012088422A1 (en) 2010-12-22 2012-06-28 Nektar Therapeutics Multi-arm polymeric prodrug conjugates of taxane-based compounds
WO2012135759A1 (en) 2011-04-01 2012-10-04 Genentech, Inc. Combinations of akt inhibitor compounds and abiraterone, and methods of use
WO2012156999A1 (en) 2011-05-19 2012-11-22 Manu Chaudhary Ready to use docetaxel formulation
US9284334B2 (en) 2011-05-19 2016-03-15 Fundación Centro Nacional De Investigaciones Oncologicas Carlos Iii Macrocyclic compounds as protein kinase inhibitors
EP2524918A1 (de) 2011-05-19 2012-11-21 Centro Nacional de Investigaciones Oncológicas (CNIO) Imidazopyrazinderivate als Kinase Inhibitoren
WO2013004984A1 (en) 2011-07-07 2013-01-10 Centro Nacional De Investigaciones Oncologicas (Cnio) Tricyclic compounds for use as kinase inhibitors
WO2013005057A1 (en) 2011-07-07 2013-01-10 Centro Nacional De Investigaciones Oncológicas (Cnio) New compounds
WO2013005041A1 (en) 2011-07-07 2013-01-10 Centro Nacional De Investigaciones Oncológicas (Cnio) Tricyclic heterocyclic compounds as kinase inhibitors
PL2753355T3 (pl) 2011-09-08 2019-04-30 Benevir Biopharm Inc Onkolityczny wirus opryszczki pospolitej i jego zastosowania lecznicze
EP2754682B1 (de) 2011-09-11 2017-06-07 Nippon Kayaku Kabushiki Kaisha Verfahren zur herstellung von blockcopolymer
US9745631B2 (en) 2011-12-20 2017-08-29 Dana-Farber Cancer Institute, Inc. Methods for diagnosing and treating oncogenic kras-associated cancer
WO2013130093A1 (en) 2012-03-02 2013-09-06 Genentech, Inc. Biomarkers for treatment with anti-tubulin chemotherapeutic compounds
CA2874521A1 (en) 2012-05-24 2013-11-28 Dana-Farber Cancer Institute, Inc. Targeting the glutamine to pyruvate pathway for treatment of oncogenic kras-associated cancer
US9107926B2 (en) 2012-06-08 2015-08-18 Genentech, Inc. Mutant selectivity and combinations of a phosphoinositide 3-kinase inhibitor compound and chemotherapeutic agents for the treatment of cancer
US20150285802A1 (en) 2012-07-18 2015-10-08 Dana-Farber Cancer Institute, Inc. Methods for treating, preventing and predicting risk of developing breast cancer
JO3685B1 (ar) 2012-10-01 2020-08-27 Teikoku Pharma Usa Inc صيغ التشتيت الجسيمي للتاكسين غير المائي وطرق استخدامها
US20140094432A1 (en) 2012-10-02 2014-04-03 Cerulean Pharma Inc. Methods and systems for polymer precipitation and generation of particles
EP2968406A4 (de) 2013-03-14 2016-10-26 Icahn School Med Mount Sinai Mit autologem tumorlysat beladener dendritischer zellimpfstoff zur behandlung von leberkrebs
US10130590B2 (en) 2013-10-01 2018-11-20 Dana-Farber Cancer Institute, Inc. Methods of treating cancer with atovaquone-related compounds
CA2942101A1 (en) 2014-03-21 2015-09-24 Abbvie Inc. Anti-egfr antibodies and antibody drug conjugates
WO2015149006A2 (en) 2014-03-27 2015-10-01 Dana-Farber Cancer Institute, Inc. Compositions and methods for modulating ncoa4-mediated autophagic targeting of ferritin
MA39818A (fr) 2014-03-30 2017-02-08 Benevir Biopharm Inc Virus oncolytiques « armés » comprenant un inhibiteur de tap exogène et leurs utilisations thérapeutiques
WO2016205429A1 (en) 2015-06-15 2016-12-22 New York University Method of treatment using oncolytic viruses
US10188626B2 (en) 2015-11-03 2019-01-29 Cipla Limited Stabilized cabazitaxel formulations
AU2017279554A1 (en) 2016-06-08 2019-01-03 Abbvie Inc. Anti-B7-H3 antibodies and antibody drug conjugates
JP2019526529A (ja) 2016-06-08 2019-09-19 アッヴィ・インコーポレイテッド 抗ｂ７−ｈ３抗体及び抗体薬物コンジュゲート
US10640563B2 (en) 2016-06-08 2020-05-05 Abbvie Inc. Anti-B7-H3 antibodies and antibody drug conjugates
CN109562168A (zh) 2016-06-08 2019-04-02 艾伯维公司 抗cd98抗体及抗体药物偶联物
MX2018015274A (es) 2016-06-08 2019-10-07 Abbvie Inc Anticuerpos anti-cd98 y conjugados de anticuerpo y farmaco.
EP3679925B1 (de) 2017-09-07 2024-10-23 Shenzhen Salubris Pharmaceuticals Co. Ltd Pharmazeutische zusammensetzung von docetaxelkonjugat und herstellungsverfahren
UY39610A (es) 2021-01-20 2022-08-31 Abbvie Inc Conjugados anticuerpo-fármaco anti-egfr

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4534899A (en) * 1981-07-20 1985-08-13 Lipid Specialties, Inc. Synthetic phospholipid compounds
US4507217A (en) * 1983-03-07 1985-03-26 Lipid Specialties, Inc. Magnetic compositions and magnetic memory devices prepared therefrom
FR2601675B1 (fr) * 1986-07-17 1988-09-23 Rhone Poulenc Sante Derives du taxol, leur preparation et les compositions pharmaceutiques qui les contiennent
US4960790A (en) * 1989-03-09 1990-10-02 University Of Kansas Derivatives of taxol, pharmaceutical compositions thereof and methods for the preparation thereof
JP2919867B2 (ja) * 1989-09-27 1999-07-19 千寿製薬株式会社 抗腫瘍剤
FR2678833B1 (fr) * 1991-07-08 1995-04-07 Rhone Poulenc Rorer Sa Nouvelles compositions pharmaceutiques a base de derives de la classe des taxanes.

Also Published As

Publication number Publication date
JP3689791B2 (ja) 2005-08-31
FI952680A0 (fi) 1995-06-01
US5438072A (en) 1995-08-01
PL309197A1 (en) 1995-09-18
AU5566994A (en) 1994-06-22
GR3032828T3 (en) 2000-06-30
WO1994012171A1 (fr) 1994-06-09
DE69328192T4 (de) 2007-07-19
DE69328192D1 (de) 2000-04-27
FI113619B (fi) 2004-05-31
HUT72650A (en) 1996-05-28
FR2698543B1 (fr) 1994-12-30
ZA938936B (en) 1994-08-03
SK281558B6 (sk) 2001-05-10
NO952151D0 (no) 1995-05-31
EP0671912A1 (de) 1995-09-20
MX9306986A (es) 1995-01-31
PL174334B1 (pl) 1998-07-31
EP0671912B1 (de) 2000-03-22
NZ258150A (en) 1996-11-26
YU74593A (sh) 1996-08-13
HK1075197A1 (en) 2005-12-09
DK0671912T3 (da) 2000-07-03
FR2698543A1 (fr) 1994-06-03
HU222833B1 (hu) 2003-11-28
ES2145115T4 (es) 2010-06-17
GEP19991856B (en) 1999-12-06
SK72595A3 (en) 1995-11-08
TW271395B (de) 1996-03-01
RU2144356C1 (ru) 2000-01-20
FI952680L (fi) 1995-06-01
CZ142195A3 (en) 1995-10-18
CA2150576C (fr) 2005-06-21
NO314436B1 (no) 2003-03-24
YU49092B (sh) 2003-12-31
KR100330316B1 (ko) 2002-11-04
ES2145115T3 (es) 2000-07-01
KR950703946A (ko) 1995-11-17
CN1636560A (zh) 2005-07-13
NO952151L (no) 1995-05-31
CN1291713C (zh) 2006-12-27
DE69328192T2 (de) 2000-09-28
CA2150576A1 (fr) 1994-06-09
HU9501596D0 (en) 1995-08-28
JPH08503689A (ja) 1996-04-23
PT671912E (pt) 2000-06-30
AU691476B2 (en) 1998-05-21
CZ284080B6 (cs) 1998-08-12
CN1090170A (zh) 1994-08-03

Similar Documents

Publication Publication Date Title
ATE190838T1 (de) Injizierbare arzneizubereitungen enthaltend taxanderivate
MY101791A (en) New benzimidazole derivatives
GR1001503B (el) Μέ?οδος δια την παρασκευή φαρμακευτικών ενώσεων αι οποίαι περιέχουν ως δραστική ουσία καρβονικά οξέα τα οποία περιέχουν ?είον κα?ώς και η χρησιμοποίησις αυτών δια την καταπολέμησιν των ρετροιών.
NO173998C (no) Analogifremgangsmaate for fremstilling av terapeutisk aktive benzimidazolderivater
FI863652A0 (fi) 7-isopropoxiisflavoninklusionskomplex bildat med cyklodextrin och ett foerfarande foer dess framstaellning.
NO963053D0 (no) Kosmetiske eller farmasöytiske preparater inneholdende mangiferin eller derivater derav
AP9801169A0 (en) N-hydroxy-B-sulfonyl propionamide derivatives.
DK0758248T3 (da) Formuleringer til faktor IX
FI921030A0 (fi) Cykliska ureaderivat, dessa foereningar innehaollande laekemedel och foerfarande foer deras framstaellning.
ATE22562T1 (de) 6-substituierte s-triazolo(3,4-a)phthalazinderivate.
IL94433A0 (en) Aminophenol derivatives,their preparation and pharmaceutical compositions containing them
MX9301783A (es) Derivados de 1-[2-arilsulfonilamino)-etil-1-oxo]-piperidina, su preparacion y su aplicacion en terapeutica.
LV10949A (lv) Aizvietoti 4-fenil-4piperidinkarboksamidi to iegusanas panemiens farmaceitiska kompozicija
ES2173858T3 (es) Analogos de huperzina a.
NZ192195A (en) 1-triazolyl-2-hydroxy-2-phenyl-3-aryl-propanes and pharmaceutical compositions
SE8405588D0 (sv) New compounds
DK0681473T3 (da) Præparater, der indeholder tandospiron eller dets analoger
ES8305783A1 (es) Procedimiento para la obtencion de derivados de aminociclitol saturados.
FI884838A0 (fi) Nytt s-timololderivat och foerfarande foer dess framstaellning.
GB1514113A (en) Therapeutic compositions containing dimercapto-diethyl ether derivatives
SE8704049D0 (sv) Novel pharmacological compounds
EP0654269A4 (de) Medizinische zusammensetzung zur hemmung von krebsmetastasierung in die leber und medizinische zusammensetzung zur behandlung des hepatoms.
JO1519B1 (en) New compounds (new benzimidazole derivatives are effective as ulcers)

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification